Efficacy of Infliximab in Pediatric Crohnʼs Disease: A Randomized Multicenter Open-Label Trial Comparing Scheduled to On Demand Maintenance Therapy

Abstract

IFX is well tolerated and safe as maintenance therapy for pediatric CD, with a clear advantage when used on a scheduled 2-month basis compared to an "on demand" basis.